Table 4 Patient baseline characteristics between the spacer group and the control group after propensity score-matching

Age, years

Median (range)

71 (55–79)

69 (56–81)

0.87

BMI, kg/m²

Median (range)

23.6 (19.7–29.7)

24.2 (20.4–38.2)

0.42

Performance status

0

15

38.5

16

41

1.0

1

24

61.5

23

59

Pre-treatment PSA, ng/mL

Median (range)

8.3 (2.3–195)

8.6 (3.9–83.1)

 ≤ 10

24

61.5

24

61.5

0.91

10–20

11

28.2

12

30.8

20 > 

4

10.3

3

7.7

Gleason score

6

3

7.7

5

12.8

0.36

7

24

61.5

28

71.8

8

6

15.4

2

5.1

9

6

15.4

4

10.3

Clinical T stage

T1c

8

20.5

13

33.3

0.49

T2a

18

46.2

18

46.2

T2b

1

2.6

2

5.1

T2c

9

23.1

4

10.3

T3a

2

5.1

2

5.1

T3b

1

2.6

0

0

Risk group

Low

2

5.1

0

0

0.4

Intermediate

25

64.1

30

76.9

High

6

15.4

4

10.3

Very high

6

15.4

5

12.8

Concurrent androgen deprivation therapy

Yes

23

59

21

53.8

0.82

No

16

41

18

46.2

PSA at RT initiation, ng/mL

Median (range)

3.4 (0.02–16.3)

3.6 (0.01–20.2)

0.78

Anti-coagulation or platelet treatment

Yes

6

15.4

5

12.8

1

No

33

84.6

34

87.2

Diabetes

Yes

5

12.8

7

17.9

0.76

No

34

87.2

32

82.1